Currently both NOX1 and NOX4 and CYP2E1 are implicated in development of inflammation and liver fibrosis [4, 33–35], whereas pharmacological inhibitors of these enzymes have been shown in vivo to prevent hepatocyte death and attenuate fibrosis progression [36, 37]. This evidence concerns the gene CYP2E1 and Hepatic fibrosis.